BioLargo expects Q1 2023 revenue >4x YoY, seventh consecutive quarterly growth record

BIOLARGO, INC.

Q1 2023 preliminary revenues expected to surpass Q4 2022 record; QoQ growth >50%.
Revenue driven by Pooph pet-odor product from Ikigai Marketing Works.
Company not yet profitable but net losses trending down as revenue increases.
2022 preliminary YoY revenue growth at least 125%; eighth consecutive annual growth.
Company expects to file 2022 annual report by end of March; earnings call April 3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.